SCHEMBL7724989

SCHEMBL7724989

CSCCN(CCC1CCCCC1)C(=O)NCCCc1ccncc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
PPARA Q07869 3/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPT P10636 2/20 0.40
PPARG P37231 2/20 0.40
USP2 O75604 2/20 0.40
GMNN O75496 1/20 0.40
USP1 O94782 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
BRCA1 P38398 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7723935 0.90 ALDH1A1 (0.39) ALDH1A1PPARAHSD17B10MAPTPPARG
Hydrochloric Acid SCHEMBL7725033 0.89 ALDH1A1 (0.38) ALDH1A1PPARAHSD17B10MAPTPPARG
SCHEMBL7723058 0.89 EPHX1 (0.46) ALDH1A1MAPTUSP2LMNATP53
SCHEMBL7723097 0.87 HSD17B10 (0.42) ALDH1A1PPARAHSD17B10MAPTPPARG
SCHEMBL7724992 0.87 ALDH1A1 (0.38) ALDH1A1PPARAHSD17B10MAPTPPARG
SCHEMBL1677553 0.87 ALDH1A1 (0.43) ALDH1A1PPARAHSD17B10MAPTPPARG
SCHEMBL7723885 0.86 HSD17B10 (0.41) ALDH1A1PPARAHSD17B10MAPTPPARG
SCHEMBL7724175 0.86 ALDH1A1 (0.38) ALDH1A1PPARAHSD17B10MAPTPPARG
Hydrochloric Acid SCHEMBL7722988 0.85 HSD17B10 (0.41) ALDH1A1PPARAHSD17B10MAPTPPARG
SCHEMBL7723950 0.85 HSD17B10 (0.43) ALDH1A1PPARAHSD17B10MAPTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420398-B2 FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-11-15 US disclosed
EP-1103543-A1 NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle TNF, UACA, HRH4 ALDH1A1 988/4885PPARA 3552/4885HSD17B10 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.